2019-02-28 01:12Business Highlights - BeiGene expanded its team to over 2,200 people and made key hires[7] - The company significantly expanded commercial capabilities and demonstrated success with its existing portfolio[7] - BeiGene is well-positioned for 2019, a potentially transformational year with key launches, data readouts, and potential filings[7] Clinical & Regulatory Progress - Zanubrutinib achieved an 84% ORR (Overall Response Rate) and 59% CR (Complete Response) in MCL (Mantle Cell Lymphoma) in China[9] - Zanubrutinib also showed an 80% ORR and 2% CR in CLL/SLL (Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma) in China[9] - Tislelizumab achieved an 86% ORR in cHL (classical Hodgkin's Lymphoma) in a China pivotal trial[9] - BeiGene initiated 7 late-stage trials for PD-1, totaling 11 ongoing trials[9] Manufacturing Expansion - BeiGene is constructing a biologics manufacturing facility in Guangzhou with an investment of over $300 million[14] - The Guangzhou facility will have a 100,000 square meter manufacturing site and a 24,000-liter commercial-scale biologics manufacturing facility[14] - The first phase of the Guangzhou manufacturing plant is planned to be completed in 2019[14] Financial Performance - BeiGene had $1,809 million in cash and short-term investments as of December 31, 2018[112] - Total revenue for 2018 was $198 million, including $131 million in product revenue and $67 million in collaboration revenue[114] - R&D expense was $679 million in 2018, compared to $269 million in 2017[115]